Bemelman FJ - Search Results

1

Risk of Pneumocystis jiroveci pneumonia in patients long after renal transplantation.

Struijk GH, Gijsen AF, Yong SL, Zwinderman AH, Geerlings SE, Lettinga KD, van Donselaar-van der Pant KA, ten Berge IJ, Bemelman FJ. Struijk GH, et al. Among authors: bemelman fj. Nephrol Dial Transplant. 2011 Oct;26(10):3391-8. doi: 10.1093/ndt/gfr048. Epub 2011 Mar 8. Nephrol Dial Transplant. 2011. PMID: 21385859

2

Biphasic granulocytopenia after administration of the first dose of OKT3.

Bemelman FJ, Buysmann S, Yong SL, van Diepen FN, Schellekens PT, ten Berge RJ. Bemelman FJ, et al. J Lab Clin Med. 1995 Dec;126(6):571-9. J Lab Clin Med. 1995. PMID: 7490516

3

Pretreatment with divided doses of steroids strongly decreases side effects of OKT3.

Bemelman FJ, Buysmann S, Surachno J, Wilmink JM, Schellekens PT, ten Berge IJ. Bemelman FJ, et al. Kidney Int. 1994 Dec;46(6):1674-9. doi: 10.1038/ki.1994.467. Kidney Int. 1994. PMID: 7700026 Free article.

4

Increase of sTNF receptor levels in acute renal allograft rejection after treatment with OKT3.

Bemelman FJ, Jansen J, van der Poll T, van Deventer SJ, ten Berge RJ. Bemelman FJ, et al. Nephrol Dial Transplant. 1994;9(12):1786-90. Nephrol Dial Transplant. 1994. PMID: 7708265

5

Toxicity of OKT3 increases with dosage: a controlled study in renal transplant recipients.

Parlevliet KJ, Bemelman FJ, Yong SL, Hack CE, Surachno J, Wilmink JM, ten Berge IJ, Schellekens PT. Parlevliet KJ, et al. Among authors: bemelman fj. Transpl Int. 1995;8(2):141-6. doi: 10.1007/BF00344424. Transpl Int. 1995. PMID: 7766296 Clinical Trial.

6

Complement activation during OKT3 treatment: a possible explanation for respiratory side effects.

Raasveld MH, Bemelman FJ, Schellekens PT, van Diepen FN, van Dongen A, van Royen EA, Hack CE, ten Berge IJ. Raasveld MH, et al. Among authors: bemelman fj. Kidney Int. 1993 May;43(5):1140-9. doi: 10.1038/ki.1993.160. Kidney Int. 1993. PMID: 8510394 Free article.

7

Activation and increased expression of adhesion molecules on peripheral blood lymphocytes is a mechanism for the immediate lymphocytopenia after administration of OKT3.

Buysmann S, Bemelman FJ, Schellekens PT, van Kooyk Y, Figdor CG, ten Berge IJ. Buysmann S, et al. Among authors: bemelman fj. Blood. 1996 Jan 1;87(1):404-11. Blood. 1996. PMID: 8547669 Free article.

8

No long-term benefit of low-dose OKT3 induction therapy in non to moderately immunized renal allograft recipients.

Bemelman FJ, Yong S, Parlevliet KJ, Surachno S, Schellekens PT, ten Berge RJ. Bemelman FJ, et al. Transplant Proc. 2002 Dec;34(8):3165-7. doi: 10.1016/s0041-1345(02)03585-6. Transplant Proc. 2002. PMID: 12493407 Clinical Trial. No abstract available.

9

Treatment of acute kidney allograft rejection with a non-mitogenic CD3 antibody.

Meijer RT, Surachno S, Yong SL, Bemelman FJ, Florquin S, Ten Berge IJ, Schellekens PT. Meijer RT, et al. Among authors: bemelman fj. Clin Exp Immunol. 2003 Sep;133(3):485-92. doi: 10.1046/j.1365-2249.2003.02200.x. Clin Exp Immunol. 2003. PMID: 12930378 Free PMC article. Clinical Trial.

10

Hyperexpression of the granzyme B inhibitor PI-9 in human renal allografts: a potential mechanism for stable renal function in patients with subclinical rejection.

Rowshani AT, Florquin S, Bemelman F, Kummer JA, Hack CE, Ten Berge IJ. Rowshani AT, et al. Kidney Int. 2004 Oct;66(4):1417-22. doi: 10.1111/j.1523-1755.2004.00903.x. Kidney Int. 2004. PMID: 15458434 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

257 results

Search Page

Filters